Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAgronomics Regulatory News (ANIC)

Share Price Information for Agronomics (ANIC)

Share Price is delayed by 15 minutes
Get Live Data
6.55    0.00 (0.00%)
Bid:
6.20
Ask:
6.90
Spread: 0.70 (11.29%)
Market Cap: £70.42m
ANIC Live PriceLast checked at - London Stock Exchange

Intraday Agronomics Share Chart

Net Asset Value(s)

8 Oct 2019 07:00

RNS Number : 0508P
Agronomics Limited
08 October 2019
 

8 October 2019

Agronomics Limited

(the "Company")

Net Asset Value calculation to 30 September 2019

Richard Reed, Chairman, commented: -

"The Net Asset Value ("NAV") calculation for the Company as at closing on 30 September 2019 was 5.50 pence per share, including un-invested cash of £3,463,359. The portfolio is valued under IFRS at bid price. I am pleased to note that the share price of 6.75 pence at 30 September 2019 close represents a premium of 22% to the NAV. Net Assets stand at £6.3 million, including investments of £2.8 million. This quarter's NAV per share represents a decrease of 23% from the previous valuation of 7.17 pence per share, which included un-invested cash of £417,952. The reduction is largely as a result of the increase in issued shares following the fundraise. No management fee is due to Shellbay Investments Limited.

Following completion of a successful fundraise during July 2019, the proceeds are now available for deployment in line with the new investment policy.

On 29 July 2019, the Company completed a subscription of US$ 699,999.54 for 885,739 Series Seed Preferred Shares in Simply Foods, Inc. ("Simply Foods") trading as New Age Meats, a company based in San Francisco, California, USA, that is developing pork-based cultured meat products. The Subscription was part of the first close of the Series Seed funding round to raise a minimum of US$ 2.0 million undertaken by Simply Foods, led by New York-based ff Graphite (V) Venture Capital Fund, LP. The Company was the only European based investor participating in this round, and remains the only UK quoted vehicle offering investors exposure to this rapidly growing sector.

On 29 August 2019, the Company completed a subscription of US$ 749,990 for 40,540 Series A Preferred Shares in BlueNalu, Inc. ("BlueNalu"), a global leader in cellular aquaculture. The subscription increased the Company's existing interest in BlueNalu to approximately 2.59%. The subscription was part of the Series A funding round undertaken by BlueNalu, and co-led by Stray Dog Ventures LLC, Clear Current Capital Fund, LLC, CPT Capital Fund, LLP and New Crop Capital Trust - four prominent investors in the alternative protein sector. The price per share of the subscription represented a multiple uplift of approximately 3.2x since the Company's original investment in BlueNalu of US$250,000 in August 2018.

On 5 September 2019, the Company subscribed for US $150,000 of convertible promissory notes in Bond Pets LLC ("Bond"). Bond makes laboratory-grown meat using fermentation for the pet food market. The subscription would translate to an approximate 3% to 4% equity interest in Bond, dependent on the valuation of Bond upon conversion.

 

Your board continues to evaluate a number of opportunities which show significant growth prospects".

Unaudited to

30 September 2019 £

Fixed Assets

Investments

2,827,203

Current Assets

Uninvested cash

3,463,359

Sundry Debtors

34,355

Current Liabilities

Trade and other creditors

(61,841)

6,263,076

Capital and Reserves

Share Capital

23

Share Premium

6,420,142

Reserves

(157,089)

6,263,076

Shares in Issue

113,795,558

Net Asset Value per share

5.50 pence

 

 

Portfolio Details

Investments as at 30 September 2019

Value

% of Total Portfolio

AgeX Therapeutics Inc

197,193

6.97%

Regent Pacific Group Limited

210,871

7.46%

Portage Biotech Inc

216,845

7.67%

Other quoted holdings

7,627

0.27%

Other unquoted holdings

2,194,667

77.63%

Total

2,827,203

100.00%

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ('MAR'). Upon the publication of this announcement via a Regulatory Information Service ('RIS'), this inside information is now considered to be in the public domain. 

 

For further information, please contact:

Agronomics Limited

Beaumont Cornish Limited

Optiva Securities Limited

Peterhouse Capital Limited

Britton Financial PR

The Company

Nomad

Joint Broker

Joint Broker

Investor Relations

Denham Eke

+44 (0) 1624 639396

Roland Cornish/James Biddle

+44 (0) 207 628 3396

Jeremy King

+44 (0) 203 137 1904

Lucy Williams

+44 (0) 207 469 0936

 

Tim Blackstone

+44 (0)7957 140416

 

ENDS

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NAVBLBDGUBGBGCR
Date   Source Headline
4th Jun 20265:59 pmRNS-RAgronomics portfolio company HydGene Update
4th Jun 20265:58 pmRNS-RAgronomics portfolio company Bond Pet Foods Update
18th May 20267:00 amRNSNet Asset Value calculation as at 31 March 2026
12th May 20267:00 amRNSAgronomics leads US$5m investment in SuperMeat
7th May 20264:04 pmRNSMeatly completes £10.4 million Series A funding
15th Apr 20261:29 pmRNS-RClean Food Group Update
14th Apr 20267:00 amRNS-RTropic’s product receives regulatory approval
1st Apr 202612:50 pmRNS-RAll G secures FDA "no questions" letter
25th Mar 20263:45 pmRNS-RClean Food Group Update
19th Mar 202612:30 pmRNS-RTropic Biosciences Update
12th Mar 20265:31 pmRNSDirector's Dealing
4th Mar 20267:00 amRNSDirector’s Dealing
25th Feb 20265:04 pmRNSDirector’s Dealing
20th Feb 20265:15 pmRNSDirector’s Dealing
19th Feb 20262:10 pmRNSDirector’s Dealing
17th Feb 20267:00 amRNSHalf-year Financial Report
13th Feb 20264:31 pmRNSResult of AGM
9th Feb 20267:00 amRNSNet Asset Value calculation as at 31 December 2025
15th Jan 20267:00 amRNSAgronomics invests A$3m in All G & Issue of Equity
30th Dec 20258:00 amRNSFinal Results and Notice of AGM
30th Dec 20258:00 amRNSFinal Results and Notice of AGM
30th Dec 20257:00 amRNSFurther equity investment in BlueNalu
30th Dec 20257:00 amRNSFurther equity investment in BlueNalu
19th Dec 20259:30 amRNSLiberation Bioindustries Series A1 equity round
19th Dec 20259:30 amRNSDissolution of Meatable
19th Dec 20259:30 amRNSDissolution of Meatable
19th Dec 20259:30 amRNSLiberation Bioindustries Series A1 equity round
21st Nov 20258:00 amRNSAgronomics invests US$ 2 million in SuperMeat
13th Nov 20257:00 amRNSNet Asset Value as at 30 September 2025
10th Nov 20257:00 amRNS-REVERY raise US$ 55 million in fresh capital
21st Oct 20257:00 amRNS-RGeltor, Inc Update
30th Sep 20257:00 amRNS-RClean Food Group Update
23rd Sep 20257:00 amRNS-ROnego Bio Update
12th Sep 20258:00 amRNS-RClean Food Group Update
22nd Aug 20258:19 amRNS-RMeatable acquires Meat Technology platform
24th Jul 20257:00 amRNS-RSolar Foods Update
18th Jul 202511:00 amRNSNet Asset Value calculation as at 30 June 2025
11th Jun 20257:00 amRNS-RAgronomics Q2 2025 Newsletter
28th May 20252:55 pmRNS-RMeatly reduces bioreactor and medium costs
12th May 20257:00 amRNSNet Asset Value calculation as at 31 March 2025
8th May 20257:00 amRNS-RLiberation Labs Announce Manufacturing Partnership
6th May 20257:00 amRNS-RMeatable and TruMeat Forge Alliance
30th Apr 20257:00 amRNS-RBlueNalu Expands Partnership with Nomad Foods
15th Apr 20259:00 amRNS-RLiberation Labs secures strategic partnership
18th Mar 20257:00 amRNSExercise of Shellbay options
14th Mar 20258:15 amRNSUnaudited Interim Results
4th Mar 20258:00 amRNS-RSolar Foods Secures €10 million Grant
7th Feb 20253:33 pmRNSResult of AGM
7th Feb 20257:00 amRNS-RMeatly launches first cultivated meat dog treat
4th Feb 20254:20 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.